Search - tctmd.com

Displaying 1 - 20 of 74

Sort: Relevancy | Date

Presentation TCT 2025

TCT 900: Comparison of Drug-Coated Balloons and The Bioadaptor in Treatment of De Novo Coronary Lesions: A 2-Year Nationwide Analysis from SWEDEHEART

Presenter: David Erlinge

October 28, 2025

Presentation TCT 2025

Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

INFINITY-SWEDEHEART-RCT 1 Year Clinical Outcomes

Presenter: David Erlinge

October 26, 2025

Presentation TCT 2024

Overview of Latest Clinical Evidence

Presenter: David Erlinge

October 30, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Presenter: David Erlinge

October 28, 2024

Presentation ESC 2024

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Presenter: David Erlinge

September 02, 2024

Presentation TCT 2023

Are Progression/Regression Studies “Good Enough” Surrogates for Rcts With Clinical Endpoints?

Presenter: David Erlinge

October 24, 2023

Presentation TCT 2023

Dynamx Bioadaptor Stent Technology

Presenter: David Erlinge

October 24, 2023

Presentation TCT 2021

What Plaque Characteristics Cause Future Events: Plaque Burden, Lipid, Ischemia, or Other?

Presenter: David Erlinge

November 06, 2021

Presentation TCT 2020

It’s All About the Plaque – Plaque Burden and Morphology Are the Most Important Predictors!

Presenter: David Erlinge

October 16, 2020

Presentation TCT 2020

PROSPECT II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients with Acute Myocardial Infarction

Presenter: David Erlinge

October 14, 2020

Presentation TCT 2019

Case #1 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

Case #1 Introduction: PCI in a Patient With ACS

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

Sweden View

Presenter: David Erlinge

September 26, 2019

Presentation TCT 2018

OAC ALONE: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

LRP: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Ron Waksman

September 24, 2018

Advertisement

TCT 900: Comparison of Drug-Coated Balloons and The Bioadaptor in Treatment of De Novo Coronary Lesions: A 2-Year Nationwide Analysis from SWEDEHEART

Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

INFINITY-SWEDEHEART-RCT 1 Year Clinical Outcomes

Overview of Latest Clinical Evidence

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Are Progression/Regression Studies “Good Enough” Surrogates for Rcts With Clinical Endpoints?

Dynamx Bioadaptor Stent Technology

What Plaque Characteristics Cause Future Events: Plaque Burden, Lipid, Ischemia, or Other?

It’s All About the Plaque – Plaque Burden and Morphology Are the Most Important Predictors!

PROSPECT II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients with Acute Myocardial Infarction

Case #1 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Case #1 Introduction: PCI in a Patient With ACS

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Sweden View

OAC ALONE: Summary and Clinical Implications

LRP: Summary and Clinical Implications

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content